The Conversation (0)
Helius Medical Technologies has extended its sole source contract with the US Army over its PoNS device testing and development.
Helius Medical Technologies (TSX:HSM, OTCQB:HSDT) has extended its sole source contract with the US Army over its PoNS device testing and development.
According to the press release:
“The contract is extended to December 31, 2017 and allows Helius to include additional study sites for the clinical trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS™) for the treatment of chronic balance deficits in subjects with mild to moderate traumatic brain injury.”
Helius’ CEO, Phil Deschamps, said the following:
“Extending this contract reflects a continued commitment from the USAMRMC, and Helius, to address the large unmet clinical need represented by both civilian and military patients that suffer chronic symptoms of traumatic brain injury.”